For instance, ImmunoGen developed a FRα-specific ADC named mirvetuximab soravtansine (under the trade name Elahere®) which was approved by the US FDA in November 2022 for the treatment of patients with epithelial ovarian cancer resistant to platinum or peritoneal cancer with three or fewer lines of prior therapies (155). Here, FOLR1 is linked to ovarian carcinoma.